Toward integrase defective lentiviral vectors for genetic immunization

Current HIV Research

Volumn 8, Issue 4, 2010, Pages 274-281

  Negr, Donatella R M ^a   Michelini, Zuleika ^a   Cara, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Immunization; Integrase; Lentiviral vector; Vaccine

Indexed keywords

ANTIGEN MPT51; CARCINOEMBRYONIC ANTIGEN; CYTOMEGALOVIRUS ANTIGEN IE1; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; HEPATITIS B SURFACE ANTIGEN; HIV POLYEPITOPE; INTEGRASE; INTEGRASE DEFECTIVE LENTIVIRUS VECTOR; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CW3; MELAN A; MELANOMA POLYEPITOPE; MYCOBACTERIUM ANTIGEN; NY ESO 1 ANTIGEN; OVALBUMIN; PROTEIN TRP2; RETROVIRUS VECTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG SAFETY; EFFECTOR CELL; GENETIC IMMUNIZATION; MACROPHAGE; MEMORY T LYMPHOCYTE; NONHUMAN; PLASMID; VIRUS DNA CELL DNA INTERACTION;

ANIMALS; ANTIBODY FORMATION; GENE THERAPY; GENETIC VECTORS; HUMANS; INTEGRASES; LENTIVIRUS; MICE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 77953513426     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791208622     Document Type: Article

References (88)

1. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol 2008; 128: 2596-605.
2. McMichael AJ. Principles of immunology. In: Warrell DA, Cox TM, Firth JD, Benz EJ, Eds. Oxford Textbook of Medicine, Fourth Edn. Oxford, Oxford University Press 2003; pp. 131-44.
3. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999; 189: 991-8.
4. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-60.
5. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101: 14567-71.
6. Relph K, Harrington K, Pandha H. Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ 2004; 329: 839-42.
7. Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-29.
8. Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 2004; 4: 861-8.
9. Voltan R, Robert-Guroff M. Live recombinant vectors for AIDS vaccine development. Curr Mol Med 2003; 3: 273-84.
10. Barquinero J, Eixarch H, Pérez-Melgosa M. Retroviral vectors: new applications for an old tool. Gene Ther 2004; 11: S3-9.
11. Chang LJ, He J. Retroviral vectors for gene therapy of AIDS and cancer. Curr Opin Mol Ther 2001; 3: 468-75.
12. Irwin MJ, Laube LS, Lee V, et al. Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J Virol 1994; 68: 5036-44.
13. rd, Chada S, et al. Evidence for localization of biologically active recombinant retroviral vector to lymph nodes in mice injected intramuscularly. Gene Ther 1996; 3: 128-36.
14. Laube LS, Burrascano M, Dejesus CE, et al. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/ REV proteins. Hum Gene Ther 1994; 5: 853-62.
15. Warner JF, Anderson CG, Laube L, et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retroviruses 1991; 7: 645-55.
16. Couzin J, Kaiser J. As Gelsinger case ends, gene therapy suffers another blow. Science 2005; 307: 1028.
17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-19.
18. Hematti P, Hong BK, Ferguson C, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2004; 2: e423.
19. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004; 2: e234.
20. Montini E, Cesana D, Schmidt M. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-96.
21. Cockrell AS, Kafri T. HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go. Curr HIV Res 2003; 1: 419-39.
22. Firat H, Zennou V, Garcia-Pons F, et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 2002; 4: 38-45.
23. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261: 120-32.
24. Pauwels K, Gijsbers R, Toelen J, et al. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 2009; 9: 459-74.
25. Schambach A, Galla M, Maetzig T, Loew R, Baum C. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167-73.
26. Schnell T, Foley P, Wirth M, Munch J, Uberla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000; 11: 439-47.
27. Zaiss AK, Son S, Chang LJ. RNA 39 readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-219.
28. Koya RC, Kasahara N, Favaro PM, et al. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 2003; 26: 451-60.
29. Palmowski MJ, Lopes L, Ikeda Y, Salio M, Cerundolo V, Collins MK. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004; 172: 1582-7.
30. Rohrlich PS, Cardinaud S, Lulè J, et al. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells. Hum Immunol 2004; 65: 514-22.
31. Schroers R, Sinha I, Segall H, et al. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol Ther 2000; 1: 171-9.
32. He Y, Falo LD Jr. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 2007; 9: 439-46.
33. Buffa V, Negri DR, Leone P, et al. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice. J Gen Virol 2006; 87: 1625-34.
34. Buffa V, Negri DR, Leone P, et al. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. Viral Immunol 2006; 19: 690-701.
35. Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vectorbased vaccine. PLoS One. 2008; 3: e3973.
36. Iglesias MC, Frenkiel MP, Mollier K, Souque P, Despres P, Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006; 8: 265-74.
37. Karwacz K, Mukherjee S, Apolonia L, et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 2009; 83: 3094-103.
38. Negri DR, Michelini Z, Baroncelli S, et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 2007; 15: 1716-23.
39. Beignon AS, Mollier K, Liard C, et al. Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques. J Virol 2009; 83: 10963-74.
40. Chinnasamy N, Treisman JS, Oaks M K, Hanson JP Jr, Chinnasamy D. Ex vivo generation of genetically modified dendritic cells for immunotherapy: implications of lymphocyte contamination. Gene Ther 2005; 12: 259-71.
41. Kung SKP, Bonifacino A, Metzger ME, Ringpis GE, Donahue RE, Chen ISY. Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum Gene Ther 2005; 16: 527-32.
42. He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and longlasting T cell responses and therapeutic immunity. J Immunol 2005; 174: 3808-17.
43. Koya RC, Kimura T, Ribas A, et al. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther 2007; 15: 971-80.
44. Wang B, He J, Liu C, Chang LJ. An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 2006; 24: 3477-89.
45. Zarei S, Abraham S, Arrighi JF, et al. Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J Virol 2004; 78: 7843-5.
46. http://www.wiley.co.uk/genmed/clinical/ Updated Dec 2009.
47. Cara A, Klotman ME. Retroviral E-DNA: persistence and gene expression in nondividing immune cells. J Leukoc Biol 2006; 80: 1013-7.
48. Banasik MB, McCray PB Jr. Integrase-defective lentiviral vectors: progress and applications. Gene Ther 2010; 17: 150-7.
49. Cara A, Reitz MS Jr. New insight on the role of extrachromosomal retroviral DNA. Leukemia 1997; 11: 1395-9.
50. Cara A, Vargas J Jr, Keller M, et al. Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA. Virology 2002; 292: 1-5.
51. Philpott NJ, Thrasher AJ. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007; 18: 483-9.
52. Wanisch K, Yáñez-Muñoz RJ. Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 2009; 17: 1316-32.
53. Farnet CM, Haseltine WA. Circularization of human immunodeficiency virus type 1 DNA in vitro. J Virol 1991; 65: 6942-52.
54. Shoemaker C, Goff S, Gilboa E, Paskind M, Mitra SW, Baltimore D. Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. Proc Natl Acad Sci USA 1980; 77: 3932-6.
55. Miller MD, Wang B, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J Virol 1995; 69: 3938-944.
56. Cornu T I, Cathomen T. Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther 2007; 15: 2107-13.
57. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298-306.
58. Vargas J Jr, Gusella GL, Najfeld V, Klotman ME, Cara A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 2004; 15: 361-72.
59. Vargas J Jr, Klotman ME, Cara A. Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. Antiviral Res 2008; 80: 288-94.
60. Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-53.
61. Apolonia L, Waddington SN, Fernandes C, et al. Stable gene transfer to muscle using nonintegrating lentiviral vectors. Mol Ther 2007; 15: 1947-54.
62. Hu B, Yang H, Dai B, Tai A, Wang P. Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 2009; 20: 1652-64.
63. Michelini Z, Negri DR, Baroncelli S, et al. Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine 2009; 27: 4622-9.
64. Negri DR, Bona R, Michelini Z, et al. Transduction of human antigen presenting cells with integrase defective lentiviral vector enables functional expansion of primed antigen specific CD8+ T cells. Hum Gene Ther 2010; Mar 8. Epub ahead of print. doi:10.1089/hum.2009.200]
65. Moldt B, Staunstrup NH, Jakobsen M, Yáñez-Muñoz RJ, Mikkelsen JG. Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC Biotechnol 2008; 8: 60.
66. Nightingale SJ, Hollis RP, Pepper KA, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006; 13: 1121-32.
67. Okada Y, Ueshin Y, Hasuwa H, Takumi K, Okabe M, Ikawa M. Targeted gene modification in mouse ES cells using integrase defective lentiviral vectors. Genesis 2009; 47: 217-23.
68. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006; 103: 17684-9.
69. Staunstrup NH, Moldt B, Mates L, et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009; 17: 1205-14.
70. Vasquez KM, Marburger K, Intody Z, Wilson JH. Manipulating the mammalian genome by homologous recombination. Proc Natl Acad Sci USA 2001; 98: 8403-10.
71. Yáñez RJ, Porter AC. Influence of DNA delivery method on gene targeting frequencies in human cells. Somat Cell Mol Genet 1999; 25: 27-31.
72. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11: 711-21.
73. Berger G, Goujon C, Darlix JL, Cimarelli A. SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther 2009; 16: 159-63.
74. Kantor B, Ma H, Webster-Cyriaque J, Monahan PE, Kafri T. Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci USA 2009; 106: 18786-91.
75. Lu R, Nakajima N, Hofmann W, et al. Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol 2004; 78: 658-68.
76. Loisel-Meyer S, Felizardo T, Mariotti J, et al. Potent induction of B-and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection. Mol Cancer Ther 2009; 8: 692-702.
77. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003; 111: 1673-81.
78. Kimura T, Koya RC, Anselmi L, et al. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther 2007; 15: 1390-99.
79. Rowe HM, Lopes L, Ikeda Y, et al. Immunization with a lentiviral vector stimulates both CD4 and CD8 T-cell responses to an ovalbumin transgene. Mol Ther 2006; 13: 310-19.
80. Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006; 13: 630-40.
81. He Y, Zhang J, Donahue C, Falo LD Jr. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006; 24: 643-56.
82. Rowe HM, Lopes L, Brown N, et al. Expression of vFLIP in a lentiviral vaccine vector activates NF-{kappa}B, matures dendritic cells, and increases CD8+ T-cell responses. J Virol 2009; 83: 1555-62.
83. Yang L, Yang H, Rideout K, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26: 326-34.
84. Iglesias MC, Mollier K, Beignon AS, et al. Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo. Mol Ther 2007; 15: 1203-10.
85. Hashimoto D, Nagata T, Uchijima M. Intratracheal administration of third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific CD8+ T-cell responses in the lung. Vaccine 2008; 26: 5095-100.
86. Arce F, Rowe HM, Chain B, Lopes L, Collins MK. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 2009; 17: 1643-50.
87. Gennari F, Lopes L, Verhoeyen E, Marasco W, Collins MK. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther 2009; 20: 554-62.
88. Kawahara M, York IA, Hearn A, Farfan D, Rock KL. Analysis of the role of tripeptidyl peptidase II in MHC class I antigen presentation in vivo. J Immunol 2009; 183: 6069-77.